Docirbrutinib

DB21606InvestigationalSmall molecule

Docirbrutinib is a small molecule drug. The usage of the INN stem '-brutinib' in the name indicates that Docirbrutinib is a agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitor. Docirbrutinib is... Docirbrutinib is under investigation in clinical trial NCT05602363 (AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma).

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₃₃H₃₁FN₆O₃ · 578.648 g/mol (avg)
Code names: AS-1763

Resolves to

Compound

UNII4E4EWP9DJQCAS2227211-00-7ChEMBLCHEMBL5077961ChEBI758600PubChem134558471

Structure

InChIKeyLJODJUIHONTDMR-UHFFFAOYSA-NSMILESNC1=NC(=C2C=C(NC2=N1)C1=CCN(CC1)C1COC1)C1=C(CO)C(=CC=C1)N1C=CC2=CC(=CC(F)=C2C1=O)C1CC1

Targets

Q06187BTK

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Docirbrutinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account